INVO Bioscience Announces Two Poster Presentations at the 2018 American Society for Reproductive Medicine (ASRM) Congress & Expo

MEDFORD, Mass., Oct. 18, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, today announced that two posters were presented at the 74th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) this past week in Denver, Colorado.

"ASRM was once again an incredible event for INVO Bioscience and our INVOcell device and procedure," commented Katie Karloff, CEO of INVO Bioscience. "INVOcell was highlighted in two poster presentations outlining the cost benefits of INVOcell's intravaginal culture system. The first, presented by Julia Butler, evaluated whether intravaginal culture is a more economical treatment for lesbian couples. The study found that when considering the all-in cost of treatment, that after 3 dIUI cycles (donor sperm with intrauterine insemination), an INVOcell cycle appears to be a more cost-effective option for lesbian couples. The second, presented by Ryan Miller, is a retrospective study aimed to assess the efficacy of the INVOcell intravaginal culture device with fresh transfers compared with intrauterine insemination (IUI) cycles at the Piedmont Reproductive Endocrinology Group, or PREG, where both are Clinical Embryologists and Lab Managers. The study concluded that the INVOcell intravaginal culture offers a significant increase in pregnancy rates compared with IUI and offers a novel treatment that gives patients an option between a simple IUI and a full IVF cycle. These studies affirm our mission to expand fertility treatment across the globe with a goal to lower the cost and increase availability of care."

Details of the poster presentations can be found on the INVO Bioscience website at https://invobioscience.com/resources/.

Is intravaginal culture a more economical treatment for lesbian couples? 
J. Butler MS, M. Darmer BS, J. Payne MD, T. McCoy MD, E. Tarnawa MD
Piedmont Reproductive Endocrinology Group, Greenville, SC

Intravaginal embryo culture: More than just a novelty? 
Ryan Miller, Travis McCoy, Edward Tarnawa, John Payne
Piedmont Reproductive Endocrinology Group, Greenville, SC
Clemson University, Clemson, SC

Additional highlights from ASRM
INVO Bioscience hosted several strategic meetings with industry leaders both from within the United States as well as internationally and assembled a KOL gathering of 30 current INVOcell adopters to discuss an array of topics, including the latest advancements in clinical management and research, and shared ideas on best practices for the INVOcell device.

INVO Bioscience's booth and participation added a critical addition to Scientific Congress & Expo by educating attendees on the novel device and procedure that provides a more natural, safe, effective and economical fertility treatment. This engagement lead to INVO Bioscience making over 200 key new contacts during the duration of the event.

Ms. Karloff concluded, "I couldn't be more pleased with the reception that we received at this year's event. It is gratifying to meet with many of our existing physicians that are utilizing INVOcell and are achieving tremendous results. Likewise, it was exciting to share the opportunity that INVOcell provides to potential new users that are looking for ways to bridge the treatment gap between providing an effective solution that can be accessible for an expanding patient population and decreased cost of care."

About INVOcell
The INVOcell device and procedure is a disruptive new technology and a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. With INVO Bioscience's mission to increase access to care and expand fertility treatment and patient care across the globe, they were a perfect addition for ASRM.

INVOcell™ key features & benefits:

• Provides a more natural incubation environment.
• Offers an affordable treatment, which may reduce the risk of wrong embryo transfers.
• Uses mild stimulation, which may reduce the risk of ovarian hyper-stimulation.
• Increases geographic accessibility (and access to care) to more patients with equivalent safety and efficacy compared to traditional IVF.
• Provides psychological benefits and promotes increased involvement by couples.
• Simpler procedure - decreases overall costs to physician and decreases patients costs by ~ 50% compared to IVF procedure rates.
• Cost per actual pregnancy may be less than multiple IUI attempts.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:

Kathleen Karloff, CEO

INVO Bioscience, Inc.

978-878-9505 ext. 504

[email protected]

SOURCE INVO Bioscience, Inc.

Related Links

http://invobioscience.com/